An observational study in Placenta Previa, sponsored by Guangzhou Institute of Respiratory Disease. Not yet recruiting. Per ClinicalTrials.gov, last updated 2024-10-01.
Sponsored by Guangzhou Institute of Respiratory Disease · Observational
This study aims to investigate the causal relationship between plasma vascular endothelial growth factor (VEGF) family proteins and placenta previa using a two-sample Mendelian randomization (MR) approach. Genome-wide association study (GWAS) data will be analyzed to assess the correlation and potential causality between VEGF protein levels and the occurrence of placenta previa.
Placenta previa is a serious complication during pregnancy, leading to significant risks for both the mother and the fetus. This study utilizes Mendelian randomization (MR) to explore the potential causal link between plasma levels of VEGF family proteins (including VEGFA, VEGFB, VEGFC, VEGFD, and PLGF) and the risk of placenta previa. By using genome-wide association study (GWAS) data from the UK Biobank and FinnGen datasets, the study aims to provide insights into the role of angiogenesis and abnormal placental development. The MR analysis will help minimize confounding factors and provide robust evidence regarding the causal relationship between VEGF proteins and placenta previa.
80 studies on the registry are indexed under Placenta Previa; 17 are open to participants now.
This study's planned enrollment of 207,473 is above the median of 100 across 32 observational studies indexed under Placenta Previa.
Browse Placenta Previa studies →Guangzhou Institute of Respiratory Disease is the lead sponsor of 99 studies on the registry; 18 are open to participants now.
Counted across the registry records on this site, refreshed daily.
This study analyzes data from European populations included in genome-wide association studies (GWAS) from UK Biobank and FinnGen, focusing on individuals with available plasma VEGF family protein levels and placenta previa data.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Causal relationship between plasma VEGFA levels and the risk of placenta previa
This outcome measures the association between plasma VEGFA levels (measured in picograms per milliliter) and the occurrence of placenta previa, using Mendelian Randomization (MR) analysis to assess causality.
Time frame: Data analysis and outcome assessment will be completed by December 2024
Causal relationship between plasma VEGFB levels and the risk of placenta previa
This outcome measures the association between plasma VEGFB levels (measured in picograms per milliliter) and the occurrence of placenta previa, using Mendelian Randomization (MR) analysis to assess causality.
Time frame: Data analysis and outcome assessment will be completed by December 2024
Causal relationship between plasma VEGFC levels and the risk of placenta previa
This outcome measures the association between plasma VEGFC levels (measured in picograms per milliliter) and the occurrence of placenta previa, using Mendelian Randomization (MR) analysis to assess causality.
Time frame: Data analysis and outcome assessment will be completed by December 2024
Causal relationship between plasma PLGF levels and the risk of placenta previa
This outcome measures the association between plasma PLGF levels (measured in picograms per milliliter) and the occurrence of placenta previa, using Mendelian Randomization (MR) analysis to assess causality.
Time frame: Data analysis and outcome assessment will be completed by December 2024
No study locations are listed for this record.
Start is estimated for Sep 2024; primary completion for Nov 2024, 1 month later.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Sep 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Guangzhou Institute of Respiratory Disease